Major Pharmaceutical Conferences and Courses.
- Published in:
- Pharmaceutical Medicine, 2018, v. 32, n. 5, p. 379, doi. 10.1007/s40290-018-0250-x
- Publication type:
- Article
Works matching IS 11782595 AND DT 2018 AND VI 32 AND IP 5
Results: 7
1
2
Forum.
- Published in:
- Pharmaceutical Medicine, 2018, v. 32, n. 5, p. 365, doi. 10.1007/s40290-018-0249-3
- Publication type:
- Article
3
Effectiveness of the Crizotinib Therapeutic Management Guide in Communicating Risks, and Recommended Actions to Minimize Risks, Among Physicians Prescribing Crizotinib in Europe.
- Published in:
- Pharmaceutical Medicine, 2018, v. 32, n. 5, p. 343, doi. 10.1007/s40290-018-0248-4
- By:
- Publication type:
- Article
4
Development of New Formulations of Biologics: Expectations, Immunogenicity, and Safety for Subcutaneous Trastuzumab.
- Published in:
- Pharmaceutical Medicine, 2018, v. 32, n. 5, p. 319, doi. 10.1007/s40290-018-0247-5
- By:
- Publication type:
- Article
5
Safety Pharmacology Study Results and their Impact on the Design of First-in-human Trials for Authorised Oncology Therapies.
- Published in:
- Pharmaceutical Medicine, 2018, v. 32, n. 5, p. 335, doi. 10.1007/s40290-018-0246-6
- By:
- Publication type:
- Article
6
Advertising of Over-the-Counter Codeine-Containing Medicines in the EU: Differences in the Regulation of Advertising Between Member States.
- Published in:
- Pharmaceutical Medicine, 2018, v. 32, n. 5, p. 327, doi. 10.1007/s40290-018-0245-7
- By:
- Publication type:
- Article
7
Spontaneous Reporting of Adverse Drug Reactions by Consumers in Comparison with Healthcare Professionals in Turkey from 2014 to 2016.
- Published in:
- Pharmaceutical Medicine, 2018, v. 32, n. 5, p. 353, doi. 10.1007/s40290-018-0244-8
- By:
- Publication type:
- Article